On February 23, Hengrui Medicine announced that it had received the "Notice of Drug Clinical Trial Approval" issued by the State Drug Administration for SHR7280 tablets, and will conduct clinical trials in the near future
.
SHR7280 is an oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, which can block the binding of endogenous GnRH to GnRH receptors, inhibiting the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) Synthesis and release of gonadal hormones, reducing levels of sex hormones such as testosterone and estradiol
.
Excessive levels of estradiol hormone can lead to the occurrence and development of uterine fibroids.
Therefore, by regulating GnRH receptors and reducing the levels of LH and FSH, uterine fibroids can be treated
.